Florida Clinical Trials Report — June 2026

For Floridians considering participation in clinical research, June 2026 presents a critical window of opportunity, with numerous new studies opening across the state, but also a significant number of trials nearing their conclusion. If you've been thinking about joining a study, now is the time to act: 272 clinical trials are slated to close within the next 90 days. This urgent call includes 55 studies actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also explore trials with impending deadlines. Research focusing on various cancers and liver conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (9 trials)
• Ovarian cancer (5 trials)
• Cancer (5 trials)
• Hepatic impairment (5 trials)
• Major depressive disorder (4 trials)
• Prostate cancer (4 trials)
• Fallopian tube cancer (4 trials)
• Advanced solid tumor (3 trials)
• Metastatic cancer (3 trials)

Major Research Initiatives Launch Across Florida

This month, Florida welcomes 90 new clinical trials, a notable increase from the 80 trials that opened in May 2026. These new studies include several significant Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like obesity and type 2 diabetes, as well as crucial vaccine development.

• AstraZeneca is sponsoring NCT07667803, a Phase 3 "Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This substantial global study aims to enroll 4,500 participants, evaluating a new treatment for weight management alongside diet and exercise.
• Another major Phase 3 trial, NCT07654361, is "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. This global study seeks 3,600 participants to assess the long-term efficacy, safety, and tolerability of aleniglipron once daily.
• Pfizer is leading two important Phase 3 vaccine trials. NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants," aims for 3,230 participants to evaluate the safety and immune response of a new vaccine against pneumonia, meningitis, and otitis media in infants. Additionally, NCT07660198, "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents," will enroll 1,200 participants to assess a new pneumococcal vaccine in older children and adolescents.
• For those with type 2 diabetes, AstraZeneca is also sponsoring NCT07662213, a Phase 3 study to find out if the study drug Elecoglipron helps adults with type 2 diabetes mellitus by comparing it with semaglutide, a medicine already used to treat type 2 diabetes mellitus. This trial plans for 1,200 participants.
• Beyond drug trials, an important observational study, NCT07645989, "Registry of Outcomes of Dezawa MuseCells®," sponsored by MuseCell Innovations Pte LTD, is seeking 5,000 participants. This registry aims to understand the long-term effects of Dezawa MuseCells in treating various diseases.
• Another significant observational study is NCT07625579, "Collaboration for Down Syndrome Progress (CDP)," sponsored by RTI International. This long-term study will follow 1,400 people with Down syndrome of all ages to better understand their health, development, and everyday experiences.
• In the realm of diagnostics, Jubaan Ltd. is sponsoring NCT07623902, "Evaluation of Gixam's Efficacy Predicting the Presence of Advanced and Non-advanced Colorectal Neoplasia in a FIT Negative Population." This study aims to enroll 1,436 participants to learn if the Gixam device effectively identifies pre-cancer or cancer in the colon and rectum in adults aged 45-84 with a negative Fecal Immunochemical Test (FIT) result.

New Research Opportunities Across Conditions and Interventions

The 90 new trials opening this month in Florida cover a diverse range of health conditions, with a strong focus on metabolic health and infectious disease prevention. The most common conditions addressed by these new studies include:

• Obesity (5 trials)
• Overweight (4 trials)
• Type 2 diabetes mellitus (4 trials)
• Breast cancer (3 trials)
• Pneumococcal disease (2 trials)
• Facial pain (2 trials)
• Chronic pain (2 trials)
• Cardiometabolic health indicators (2 trials)
• Migraine (2 trials)
• Healthy adult participants (2 trials)

In terms of intervention types, drug trials lead the way, accounting for 48 of the new studies. Other types of research include device trials (15), behavioral interventions (8), and biological treatments (3).

Geographic Reach: Florida's Research Hubs Expand

Florida's clinical research landscape continues to be robust, with 3,840 clinical trials currently recruiting across 199 cities and 4,565 research sites statewide. This month, the majority of new research initiatives are concentrated in major metropolitan areas, ensuring broad access for residents. The cities with the most new trials include:

• Miami (24 new trials)
• Jacksonville (17 new trials)
• Orlando (16 new trials)
• Tampa (13 new trials)
• Maitland (8 new trials)
• Ocala (7 new trials)
• Leesburg (6 new trials)
• Ocoee (5 new trials)
• Hollywood (5 new trials)
• Miami Lakes (4 new trials)

This distribution ensures that residents in various regions of Florida have access to cutting-edge research, with significant opportunities available from the bustling south to the northern parts of the state.

Healthy Volunteers and Diverse Demographics Welcome

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 90 new trials launched this month, 22 are actively seeking healthy volunteers. Statewide, a total of 442 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Florida are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 13 include children as participants, and 69 include older adults, ensuring that research benefits diverse age groups. Additionally, 7 new trials are female-only, and 3 are male-only, addressing specific health needs. Academic institutions like Florida State University, University of Miami, Mayo Clinic, and University of Florida are playing a vital role in the state's research ecosystem, sponsoring a combined total of 18 new trials. Industry sponsors are also driving significant research efforts, with 59 new trials sponsored by pharmaceutical companies such as AstraZeneca, Pfizer, and Novo Nordisk A/S.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Florida.